RT Journal Article
SR Electronic
T1 Neuroanatomical correlates of polygenic risk for Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.17.22269262
DO 10.1101/2022.01.17.22269262
A1 Abbasi, Nooshin
A1 Tremblay, Christina
A1 Rajimehr, Reza
A1 Yu, Eric
A1 Markello, Ross D
A1 Shafiei, Golia
A1 Khatibi, Nina
A1 The ENIGMA-Parkinson’s study
A1 Jahanshad, Neda
A1 Thompson, Paul M.
A1 Gan-Or, Ziv
A1 Misic, Bratislav
A1 Dagher, Alain
YR 2022
UL http://medrxiv.org/content/early/2022/11/28/2022.01.17.22269262.abstract
AB Parkinson ‘s Disease (PD) is heritable, however how genetic risk confers vulnerability remains mostly unknown. Here we use genetic and neuroimaging measures from 20,000 healthy adults from the UK Biobank to show that PD polygenic risk score (PRS) is associated with cortical thinning in a pattern that resembles cortical atrophy seen in PD. Conversely, PD PRS is associated with a global increase in cortical surface area. We also show that the genetically determined cortical thinning profile overlaps with the expression of genes associated with synaptic signaling, is dependent on anatomical connectivity and on regional expression of the most significant PD risk genes. Despite identical PRS distributions in males and females, only males show the associated brain features, possibly explaining the sex disparity in PD. We discuss potential mechanisms linking genetic risk to cortical thickness and surface area, and suggest that the divergent effects may reflect separate routes of genetic vulnerability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the Canadian Institutes of Health Research the Michael J Fox Foundation for Parkinson's Research the Alzheimer's Association the Weston Brain Institute and the Healthy Brains for Healthy Lives (HBHL) initiative of McGill University. NA received a scholarship from the Montreal Neurological Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee/IRB of the McGill University Health Centre gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ukbiobank.ac.uk/ https://www.ppmi-info.org/ https://alleninstitute.org/